Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherap

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC

Based on a subgroup analysis, improvement in event-free survival with the KEYTRUDA-based regimen was consistent across all PD-L1 expression subgroups, histology and stage

Exploratory subgroup... | June 3, 2023

Related Keywords

Canada , United States , American , , Exchange Commission , Drug Administration , Statement Of Merck Co Inc , Facebook , Instagram , Merck Co Inc , Linkedin , Youtube , Twitter , American Society Of Clinical Oncology , Clinical Oncology , Annual Meeting , New England Journal , Biologics License Application , Prescription Drug User Fee Act , Bacillus Calmette Guerin , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse , Which Can Present With Diabetic , Nervous System , Connective Tissue , Patients With Multiple , Neck Squamous Cell , Mismatch Repair Deficient , Mismatch Repair Deficient Colorectal , Looking Statement , Securities Litigation Reform Act , Annual Report , Merck Co , Nc Stock Exchange , News , Information , Press Release , Ased , N , Subgroup , Improvement , Survival , Ith , The , Regimen , Gas , Consistent , Cross , Wall , Expression , Distology , Nd Mrk Us58933y1055 ,